Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo

Sep 17 2012

• By Paul Bonanos

Related Content

Does Bristol Nuc’s Possible Cardiac Toxicity Portend A Class Effect?

Aug 06 2012

The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill <em>Stribild</em>

Aug 27 2012

Gilead/Bristol Hep C Combo Gets High Marks At EASL, But Its Future Is In Doubt

Apr 23 2012

Gilead Complera Launch Imminent Following FDA Approval

Aug 11 2011

Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera

Oct 28 2011

Gilead Springs Further Into Oncology With Calistoga Acquisition

Feb 22 2011

HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex

Jan 09 2012

Related Companies

Gilead Sciences, Inc.

Johnson & Johnson

Johnson & Johnson

Pharmasset, Inc.

Bristol Myers Squibb Company

Inhibitex, Inc.

Calistoga Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Launches BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window